相关实验视频
Updated: Sep 10, 2025
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
36.8K
miR-361-5p有助于阿尔茨海默病的发生
Abbas Jalaiei1, Jalal Gharesouran1, Shahram Arsang-Jang2
1Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Scientific reports
|August 23, 2025
概括
研究人员在阿尔茨海默病 (AD) 中研究了HOMER1,ATAD1和miR-361. 在AD中,大脑组织显示HOMER1,ATAD1和miR-361的降低,但只有miR-361在患者血液中较低,这表明它具有潜在的生物标志物.
科学领域:
- 神经科学
- 遗传学
- 生物标志物发现
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响认知功能.
- 突触功能障碍和神经炎症是阿尔茨海默病的关键病理特征.
- 确定早期阿尔茨海默病诊断和进展的可靠生物标志物至关重要.
研究的目的:
- 研究HOMER1,ATAD1和miR-361在阿尔茨海默病 (AD) 发病过程中的作用.
- 探索这些分子作为阿尔茨海默病的生物标志物的潜力.
主要方法:
- 对脑组织进行微阵列分析 (GSE106241,GSE157239;n=60),以评估基因表达.
- 对脑组织和血液样本进行逆转录聚合酶链反应 (RT-PCR) (n=100;50名阿尔茨海默病患者,50名对照组).
- 对阿尔茨海默病的不同布拉克阶段的基因表达分析.
主要成果:
- 在AD脑组织中观察到HOMER1和ATAD1调节者的表达减少.
- 在AD脑组织中,miR-361的表达也减少了.
- 虽然HOMER1和ATAD1在血液样本中没有显著差异,但miR-361在AD患者的血液中显著较低 (调整后p < 0. 043).
结论:
- 大脑组织中HOMER1,ATAD1和miR-361的失调与AD中的突触功能障碍和神经炎症有关.
- 作为阿尔茨海默病的外围生物标志物,miR-361具有潜力.
- 需要使用更大的样本进行进一步的研究,以验证这些发现并探索它们的临床实用性.
相关概念视频
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
03:03Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K